Markets:

Overview

News

Currencies

International

Treasuries

Clearmind Medicine Inc. - Common Shares (NQ:CMND)

0.1525 -0.0075 (-4.69%)

Streaming Delayed Price Updated: 12:17 PM EST, Nov 26, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Clearmind Medicine Inc. - Common Shares

< Previous 1 2 3 4 5 6 7 8 9

...

12 13 Next >

Clearmind Medicine to Present Groundbreaking Research at Psychedelic Medicine – Israel 2024 Conference

July 12, 2024

From Clearmind Medicine Inc.

Via GlobeNewswire

Why Psychedelic-Pharma Clearmind Medicine Stock Is Moving Higher ↗

June 28, 2024

Clearmind Medicine shares are trading higher Friday after the company announced advancement in its proprietary MEAI-based binge behavior regulator program through the granting of patent approval in...

Via Benzinga

Topics Intellectual Property

Clearmind Medicine Granted Patent Approval in Hong Kong for its Binge Behaviors Treatment

June 28, 2024

From Clearmind Medicine Inc.

Via GlobeNewswire

Day Trading My Way From Red To Green ↗

June 23, 2024

I set daily profit goals and max loss limits to manage my risk. My daily goal is $5,000, and I cap my daily loss at the same amount.

Via Talk Markets

CMND Stock Earnings: Clearmind Medicine Reported Results for Q2 2024 ↗

June 17, 2024

Clearmind Medicine just reported results for the second quarter of 2024.

Via InvestorPlace

Clearmind Medicine Secured Exclusive Global Rights to Innovative Psychedelic Compounds for PTSD Treatment

June 20, 2024

From Clearmind Medicine Inc.

Via GlobeNewswire

What's Going On With Clearmind Medicine Stock Tuesday? ↗

June 11, 2024

Clearmind said its alcohol substitute was granted patents in the U.S., India and Europe. The company also highlighted that the no/low alcohol category is forecasted to grow at a volume CAGR of more...

Via Benzinga

Topics Intellectual Property

Clearmind Medicine Revolutionizes the $13 Billion NonAlcoholic Beverages Market with its Psychedelic-Based Drink

June 11, 2024

From Clearmind Medicine Inc.

Via GlobeNewswire

Clearmind Medicine Advances its Proprietary Psychedelic- Based Synthetic Alcohol Beverage Product

May 10, 2024

From Clearmind Medicine Inc.

Via GlobeNewswire

Why Beyond Shares Are Trading Lower By Over 20%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session ↗

May 07, 2024

Via Benzinga

Why Clearmind Medicine Stock Is Moving Higher ↗

May 07, 2024

Clearmind Medicine shares are up Tuesday after the company announced it signed an exclusive patent licensing agreement with Yissum Research Development.

Via Benzinga

Topics Intellectual Property

Clearmind Medicine Secures Exclusive Global Rights to Breakthrough Psychedelic Compounds for PTSD Treatment

May 07, 2024

From Clearmind Medicine Inc.

Via GlobeNewswire

Clearmind Applies to Cease Being a Reporting Issuer in Canada

April 30, 2024

From Clearmind Medicine Inc.

Via GlobeNewswire

Psychedelics Headlines: Dementia Prevention, Psychological Flexibility, Ancient Romans' Trips And More ↗

April 17, 2024

Via Benzinga

Psyched: DEA Revisits Ban On Two Psychedelics, Farewell Russell Newcombe, Podcast Episode On Kanna & More ↗

April 17, 2024

Via Benzinga

Clearmind Medicine Announces Exclusive Licensing Agreement for Generation 3.0 Psychedelic Compounds for the Treatment of Mental Disorders

April 17, 2024

From Clearmind Medicine Inc.

Via GlobeNewswire

Clearmind Medicine Files U.S. Patent Application for Psychedelic-Based Treatment for Eating Disorders

April 10, 2024

From Clearmind Medicine Inc.

Via GlobeNewswire

Clearmind Medicine CEO Issues Letter to Shareholders

April 09, 2024

From Clearmind Medicine Inc.

Via GlobeNewswire

Psychedelics Headlines: A Form Of Life, Treating Chronic Pain, Microdosing And More ↗

March 30, 2024

Via Benzinga

Psyched: 5-MeO-DMT For Depression, Utah Hospitals Providing Therapy, Elon Musk And Meta's Influence ↗

March 29, 2024

Via Benzinga

Clearmind Medicine Announces International Patent Application for Preventing and Treating Depression

March 27, 2024

From Clearmind Medicine Inc.

Via GlobeNewswire

Psyched: LSD, Psilocybin As Breakthrough Therapies, $14M Fed Grant For Ibogaine, Indiana's Research And More ↗

March 20, 2024

Via Benzinga

Topics Economy

Why Taysha Gene Therapies Shares Are Trading Higher By Around 27%; Here Are 20 Stocks Moving Premarket ↗

March 20, 2024

Shares of Taysha Gene Therapies, Inc. (NASDAQ: TSHA) rose sharply in today’s pre-market trading after the company reported a year-over-year increase in FY23 EPS results.

Via Benzinga

Breakthrough in Wellness: Clearmind Medicine's Psychedelic Treatment Granted Divisional Patent Approval in China

March 19, 2024

From Clearmind Medicine Inc.

Via GlobeNewswire

Psychedelics Headlines: Substitution Survey, Frank Herbert's Magic Mushrooms, Celestial Plans And News Review ↗

March 16, 2024

Via Benzinga

Clearmind Medicine Obtains Clearance for its Psychedelic- Based Alcoholism Clinical Trial

March 13, 2024

From Clearmind Medicine Inc.

Via GlobeNewswire

Clearmind Medicine Received Approval for a Voluntary Delisting of its Common Shares From the Canadian Securities Exchange

March 13, 2024

From Clearmind Medicine Inc.

Via GlobeNewswire

Podcast: Clearmind's Non-Hallucinogenic Psychoactive Molecule Could Become A Solution For Addictive Behaviors ↗

March 12, 2024

Via Benzinga

Psyched: New Evidence Shows Psilocybin As Anxiety Therapy, Open-Source Learning For Therapists, Enveric's Licensing Deals And More ↗

March 04, 2024

Via Benzinga

SciSparc-Clearmind Partnership Yields Three New International Patent Applications for MDMA, Ibogaine and Ketamine Compounds

February 27, 2024

From SciSparc Ltd

Via GlobeNewswire

< Previous 1 2 3 4 5 6 7 8 9

...

12 13 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.